Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | ABL1 | P00519 | 2/20 | 0.50 |
| ▸ | BCR | P11274 | 2/20 | 0.50 |
| ▸ | GPR183 | P32249 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MGLL | Q99685 | 1/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24185306 | 0.86 | HPGD (0.64) | HPGDPOLBCA12CA1CA2 | |
| SCHEMBL3396445 | 0.86 | HPGD (0.68) | HPGDPOLBCA12CA1CA2 | |
| SCHEMBL24185308 | 0.83 | HPGD (0.60) | HPGDPOLBCA12CA1CA2 | |
| SCHEMBL12546934 | 0.82 | HPGD (0.50) | HPGDPOLBL3MBTL3L3MBTL1ALDH1A1 | |
| SCHEMBL4007190 | 0.82 | CA12 (0.57) | HPGDPOLBCA12CA1CA2 | |
| SCHEMBL12629123 | 0.82 | ALDH1A1 (0.62) | HPGDLMNAALDH1A1MGLLHSD11B1 | |
| SCHEMBL14486 | 0.82 | ALDH1A1 (0.50) | HPGDPOLBCA12CA1CA2 | |
| SCHEMBL6595655 | 0.81 | HPGD (0.72) | HPGDPOLBCA12CA1CA2 | |
| SCHEMBL2616939 | 0.81 | HPGD (0.63) | HPGDPOLBCA12CA1CA2 | |
| SCHEMBL971083 | 0.81 | HPGD (1.00) | HPGDPOLBCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024511-B2 | Substituted imidazo[1,2-a]pyridin-2-ylamine compounds, and pharmaceutical compositions and methods of use thereof | SHANGHAI FUDAN-ZHANGJIANG BIO-PHARMACEUTICAL CO., LTD. (CN) | 2024-07-02 | — | — | US | disclosed |
| US-12024511-B2 | Substituted imidazo[1,2-a]pyridin-2-ylamine compounds, and pharmaceutical compositions and methods of use thereof | SHANGHAI FUDAN-ZHANGJIANG BIO-PHARMACEUTICAL CO., LTD. (CN) | 2024-07-02 | — | — | US | disclosed |
| US-20230373985-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | ORIGENIS GMBH (DE) | 2023-11-23 | — | — | US | disclosed |
| US-20230373985-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | ORIGENIS GMBH (DE) | 2023-11-23 | — | — | US | disclosed |
| WO-2022011337-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | ORIGENIS GMBH (DE) | 2022-01-13 | — | — | WO | disclosed |
| WO-2022011338-A2 | KINASE MODULATORS AND METHODS OF USE THEREOF | ORIGENIS GMBH (DE) | 2022-01-13 | — | — | WO | disclosed |
| US-20200361934-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDIN-2-YLAMINE COMPOUNDS, AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | JN THERAPEUTICS LTD. (CN) | 2020-11-19 | — | — | US | disclosed |
| US-10730875-B2 | Substituted imidazo[1,2-A]pyridin-2-ylamine compounds, and pharmaceutical compositions and methods of use thereof | JN THERAPEUTICS (CN) | 2020-08-04 | — | — | US | disclosed |
| US-20190284185-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDIN-2-YLAMINE COMPOUNDS, AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | JN THERAPEUTICS LTD. (CN) | 2019-09-19 | — | — | US | disclosed |
| US-20180002328-A1 | SUBSTITUTED IMIDAZO[1, 2-A]PYRIDIN-2-YLAMINE COMPOUNDS, AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | JN THERAPEUTICS LTD. (CN) | 2018-01-04 | — | — | US | disclosed |
| US-20090275569-A1 | Benzotriazine Inhibitors of Kinases | TARGEGEN, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090275569-A1 | Benzotriazine Inhibitors of Kinases | TARGEGEN, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | disclosed |
| WO-2009098236-A1 | PYRROLO [2, 3-D] PYRIDINES AND USE THEREOF AS TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-08-13 | — | — | WO | disclosed |
| US-7456176-B2 | Benzotriazine inhibitors of kinases | TARGEGEN, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456176-B2 | Benzotriazine inhibitors of kinases | TARGEGEN, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456176-B2 | Benzotriazine inhibitors of kinases | TARGEGEN, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| EP-1809614-A2 | BENZOTRIAZINE INHIBITORS OF KINASES | Targegen, Inc. (US) | 2007-07-25 | — | — | EP | disclosed |
| US-20050245524-A1 | Benzotriazine inhibitors of kinases | TARGEGEN, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| WO-2005096784-A2 | BENZOTRIAZINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373985-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | TYK2, MAPKAPK2, MAP3K20 | HPGD 4226/4885POLB 1388/4885CA12 4754/4885 |
| US-20190284185-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDIN-2-YLAMINE COMPOUNDS, AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | JAK1, JAK2, JAK3 | HPGD 1286/4885POLB 3310/4885CA12 4811/4885 |
| US-20090275569-A1 | Benzotriazine Inhibitors of Kinases | SRC, CAMK4, CAMK2G | HPGD 3691/4885POLB 4627/4885CA12 4449/4885 |
| US-20050245524-A1 | Benzotriazine inhibitors of kinases | SRC, CAMK4, CAMK2G | HPGD 3691/4885POLB 4627/4885CA12 4449/4885 |
| US-12024511-B2 | Substituted imidazo[1,2-a]pyridin-2-ylamine compounds, and pharmaceutical compositions and methods of use thereof | JAK1, JAK2, JAK3 | HPGD 1286/4885POLB 3310/4885CA12 4811/4885 |
| US-10730875-B2 | Substituted imidazo[1,2-A]pyridin-2-ylamine compounds, and pharmaceutical compositions and methods of use thereof | JAK1, JAK2, JAK3 | HPGD 1286/4885POLB 3310/4885CA12 4811/4885 |
| US-20200361934-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDIN-2-YLAMINE COMPOUNDS, AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | JAK1, JAK2, JAK3 | HPGD 1286/4885POLB 3310/4885CA12 4811/4885 |
| US-20180002328-A1 | SUBSTITUTED IMIDAZO[1, 2-A]PYRIDIN-2-YLAMINE COMPOUNDS, AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | JAK1, JAK2, JAK3 | HPGD 1286/4885POLB 3310/4885CA12 4811/4885 |
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | ABL1, JAK2, JAK1 | HPGD 1215/4885POLB 4649/4885CA12 3877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.